Christopher Romero, MD, PhD, FACP, Medical Director at Headlands Research and Principal Investigator at Headlands Research Brownsville, collaborated on a phase 2 study evaluating maridebart cafraglutide (MariTide), a novel long-acting peptide-antibody conjugate designed to treat obesity.
The study found that once-monthly administration of MariTide led to substantial and sustained weight reduction in participants with obesity, with or without type 2 diabetes, and favorable effects on glycemic control.
Read the full publication in the New England Journal of Medicine.